Viewing Study NCT01925235


Ignite Creation Date: 2025-12-24 @ 10:35 PM
Ignite Modification Date: 2025-12-30 @ 6:03 AM
Study NCT ID: NCT01925235
Status: COMPLETED
Last Update Posted: 2013-08-19
First Post: 2013-08-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Analysis of Remote-ischemic Preconditioning Effects on Kidney Function
Sponsor: University of Cologne
Organization:

Study Overview

Official Title: Remote Ischemic Preconditioning Effects on Kidney Function in Patients Receiving Transcatheter Aortic Valve Implantation
Status: COMPLETED
Status Verified Date: 2013-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: RenPRO-TAVI
Brief Summary: Patients with impaired renal function are at elevated risk for development of acute kidney injury (AKI). AKI is associated with increased risk for cardiovascular morbidity and mortality. Effective AKI prevention strategies are needed. Remote ischemic preconditioning (RIPC) is a novel and successful strategy to attenuate contrast medium induced AKI in patients undergoing elective coronary angiography.

The retrospective RenPro-TAVI Trial was designed to test the hypothesis whether remote ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter aortic valve implantation (TAVI).

Patients with impaired renal function undergoing TAVI will be evaluated in respect whether they received remote ischemic preconditioning before the procedure or not. This study will give insight if RIPC might be beneficial in these patients.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: